653 related articles for article (PubMed ID: 21521830)
21. New paradigms in the surgical and adjuvant treatment of ovarian cancer.
Hodeib M; Eskander RN; Bristow RE
Minerva Ginecol; 2014 Apr; 66(2):179-92. PubMed ID: 24848076
[TBL] [Abstract][Full Text] [Related]
22. Ovarian cancer.
Matulonis UA; Sood AK; Fallowfield L; Howitt BE; Sehouli J; Karlan BY
Nat Rev Dis Primers; 2016 Aug; 2():16061. PubMed ID: 27558151
[TBL] [Abstract][Full Text] [Related]
23. Recent advances in the management of women with ovarian cancer.
Eltabbakh GH
Minerva Ginecol; 2004 Feb; 56(1):81-9. PubMed ID: 14973412
[TBL] [Abstract][Full Text] [Related]
24. Whole-body hyperthermia in combination with platinum-containing drugs in patients with recurrent ovarian cancer.
Douwes F; BogoviC J; Douwes O; Migeod F; Grote C
Int J Clin Oncol; 2004 Apr; 9(2):85-91. PubMed ID: 15108039
[TBL] [Abstract][Full Text] [Related]
25. Epigenetic biomarkers in epithelial ovarian cancer.
Gloss BS; Samimi G
Cancer Lett; 2014 Jan; 342(2):257-63. PubMed ID: 22245949
[TBL] [Abstract][Full Text] [Related]
26. The potential for risk stratification in the management of ovarian cancer risk.
Pharoah PD
Int J Gynecol Cancer; 2012 May; 22 Suppl 1():S16-7. PubMed ID: 22543912
[TBL] [Abstract][Full Text] [Related]
27. Ovarian cancer treatment in mutation carriers/BRCAness.
Lorusso D; Perotto S
Minerva Ginecol; 2016 Oct; 68(5):566-78. PubMed ID: 26785283
[TBL] [Abstract][Full Text] [Related]
28. PARP inhibitors and epithelial ovarian cancer: an approach to targeted chemotherapy and personalised medicine.
Mukhopadhyay A; Curtin N; Plummer R; Edmondson RJ
BJOG; 2011 Mar; 118(4):429-32. PubMed ID: 21244617
[TBL] [Abstract][Full Text] [Related]
29. Germline and somatic mutations in homologous recombination genes among Chinese ovarian cancer patients detected using next-generation sequencing.
Zhao Q; Yang J; Li L; Cao D; Yu M; Shen K;
J Gynecol Oncol; 2017 Jul; 28(4):e39. PubMed ID: 28541631
[TBL] [Abstract][Full Text] [Related]
30. The American Society of Peritoneal Surface Malignancies Multi-Institution evaluation of 1,051 advanced ovarian cancer patients undergoing cytoreductive surgery and HIPEC: An introduction of the peritoneal surface disease severity score.
Foster JM; Sleightholm R; Smith L; Ceelen W; Deraco M; Yildirim Y; Levine E; Muñoz-Casares C; Glehen O; Patel A; Esquivel J
J Surg Oncol; 2016 Dec; 114(7):779-784. PubMed ID: 27792292
[TBL] [Abstract][Full Text] [Related]
31. Genetic heterogeneity after first-line chemotherapy in high-grade serous ovarian cancer.
Lambrechts S; Smeets D; Moisse M; Braicu EI; Vanderstichele A; Zhao H; Van Nieuwenhuysen E; Berns E; Sehouli J; Zeillinger R; Darb-Esfahani S; Cacsire Castillo-Tong D; Lambrechts D; Vergote I
Eur J Cancer; 2016 Jan; 53():51-64. PubMed ID: 26693899
[TBL] [Abstract][Full Text] [Related]
32. Prevention and early detection of ovarian cancer: mission impossible?
Bast RC; Brewer M; Zou C; Hernandez MA; Daley M; Ozols R; Lu K; Lu Z; Badgwell D; Mills GB; Skates S; Zhang Z; Chan D; Lokshin A; Yu Y
Recent Results Cancer Res; 2007; 174():91-100. PubMed ID: 17302189
[TBL] [Abstract][Full Text] [Related]
33. Frontline treatment of epithelial ovarian cancer.
Goh J; Mohan GR; Ladwa R; Ananda S; Cohen PA; Baron-Hay S
Asia Pac J Clin Oncol; 2015 Dec; 11 Suppl 6():1-16. PubMed ID: 26669253
[TBL] [Abstract][Full Text] [Related]
34. HIPEC ROC I: a phase I study of cisplatin administered as hyperthermic intraoperative intraperitoneal chemoperfusion followed by postoperative intravenous platinum-based chemotherapy in patients with platinum-sensitive recurrent epithelial ovarian cancer.
Zivanovic O; Abramian A; Kullmann M; Fuhrmann C; Coch C; Hoeller T; Ruehs H; Keyver-Paik MD; Rudlowski C; Weber S; Kiefer N; Poelcher ML; Thiesler T; Rostamzadeh B; Mallmann M; Schaefer N; Permantier M; Latten S; Kalff J; Thomale J; Jaehde U; Kuhn WC
Int J Cancer; 2015 Feb; 136(3):699-708. PubMed ID: 24895230
[TBL] [Abstract][Full Text] [Related]
35. The role of hyperthermic intraperitoneal chemotherapy using paclitaxel in platinum-sensitive recurrent epithelial ovarian cancer patients with microscopic residual disease after cytoreduction.
Cascales-Campos PA; Gil J; Feliciangeli E; Gil E; González-Gil A; López V; Ruiz-Pardo J; Nieto A; Parrilla JJ; Parrilla P
Ann Surg Oncol; 2015 Mar; 22(3):987-93. PubMed ID: 25212832
[TBL] [Abstract][Full Text] [Related]
36. Diagnosis and management of epithelial ovarian cancer.
Bhoola S; Hoskins WJ
Obstet Gynecol; 2006 Jun; 107(6):1399-410. PubMed ID: 16738170
[TBL] [Abstract][Full Text] [Related]
37. Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer.
Konstantinopoulos PA; Spentzos D; Karlan BY; Taniguchi T; Fountzilas E; Francoeur N; Levine DA; Cannistra SA
J Clin Oncol; 2010 Aug; 28(22):3555-61. PubMed ID: 20547991
[TBL] [Abstract][Full Text] [Related]
38. [Epithelial ovarian cancer: what is the consensus in 1995?].
Chevallier B; Dessogne P
Bull Cancer; 1995 Nov; 82(11):923-8. PubMed ID: 8535018
[TBL] [Abstract][Full Text] [Related]
39. The role of cytoreductive surgery and HIPEC in epithelial ovarian cancer.
Halkia E; Spiliotis J
J BUON; 2015 May; 20 Suppl 1():S12-28. PubMed ID: 26051328
[TBL] [Abstract][Full Text] [Related]
40. Management of early ovarian cancer.
Sonoda Y
Oncology (Williston Park); 2004 Mar; 18(3):343-56; discussion 358, 361-2. PubMed ID: 15065703
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
